GLP-1 receptor agonists were not clearly linked with Parkinson's disease in humans (Patients with type 2 diabetes initiating therapy; compared with new metformin users) (aHR 0.91, 95% CI 0.79–1.05).
“The overall PD risk was comparable between GLP-1RA and metformin groups (aHR, 0.91; 95% CI, 0.79-1.05).”
HumansPatients with type 2 diabetes initiating therapy; compared with new metformin users
GLP-1 receptor agonists were not clearly linked with Parkinson's disease in humans (compared with dipeptidyl peptidase-4 inhibitors) (HR 1.04 [95% CI 0.93 to 1.17]).
“hazard ratios for dementia, Alzheimer's disease, vascular dementia, and Parkinson's disease onset were 0.76 [0.72 to 0.81], 0.77 [0.68 to 0.87], 0.75 [0.67 to 0.85], and 1.04 [0.93 to 1.17]”
Humanscompared with dipeptidyl peptidase-4 inhibitors4.0-year mean follow-upn = 214,442
GLP-1 receptor agonists were not clearly linked with Parkinson's disease in obese patients, all GLP-1 receptor agonist users (RR 0.784, 95% CI 0.580-1.058).
“The risk reduction for Parkinson's disease was not statistically significant overall (RR = 0.784, 95 %CI = 0.580-1.058)”
Humansin obese patients, all GLP-1 receptor agonist users
Physical activity was not clearly linked with Parkinson's disease in humans (prodromal Parkinson's disease) (p-values > 0.05).
“physical activity (as assessed by the total, household-related, leisure-related, and work-related scores) had no significant associations with disease severity and cognitive function (p-values > 0.05)”
Proton-pump inhibitors were not clearly linked with Parkinson's disease in humans (Adults with upper gastrointestinal disorders; overall use; IPTW analysis) (IPTW HR 0.95 (95% CI 0.89–1.02); PSM HR 0.93 (95% CI 0.84–1.03)).
“Overall PPI use was not significantly associated with PD risk”
HumansAdults with upper gastrointestinal disorders; overall use; IPTW analysisseven years preceding the index date
Estradiol was not clearly linked with Parkinson's disease in humans (tested by mediation analysis with 2,000 bootstrap resamples) (indirect effect = -0.0054, P = 0.300; 5.7% mediated).
“Estradiol did not mediate the MetS-PD association (indirect effect = − 0.0054, P = 0.300; 5.7% mediated).”
Humanstested by mediation analysis with 2,000 bootstrap resamplesfemales
Parkinson's disease is linked with worse gait speed in humans (compared to controls).
“Compared to controls, participants with PD showed poorer gait performance, with lower preferred walking speed and shorter step length in both gait conditions.”
Parkinson's disease is linked with worse gait speed in humans (participating in a community-based exercise program).
“Adults with PD showed significantly lower physical performance than community-dwelling older adults, with gait speed exhibiting the largest between-group difference.”
Humansparticipating in a community-based exercise program
Parkinson's disease decreases cognitive function in humans.
“Performance followed expected significant trends across language-speaking cohorts: young adults (YA)>older adults (OA)>people with Parkinson's Disease (PwP), confirming discriminative abilities.”
Parkinson's disease impairs cognitive function in humans (all conditions collapsed).
“All conditions collapsed, the efficiency of the cognitive task was significantly lower in PwPD than HE, whilst accuracy was affected to a lower extent.”
Parkinson's disease is linked with worse cognitive function in humans (compared to age-matched healthy controls).
“Compared to age-matched healthy controls, people with PD (pwPD) showed impaired cognitive performance, alongside reduced central functional connectivity.”
Parkinson's disease is linked with worse physical function in humans (Parkinson's disease) (SPPB: p = 0.004; TUG: p = 0.002; walking speed: p = 0.001).
“poorer physical function (SPPB: p = 0.004; TUG: p = 0.002; walking speed: p = 0.001)”
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·
Parkinson's disease showed no clear effect on zonulin in humans (Parkinson's disease compared to non-PD) (MD = 26.88 ng/mL; 95 % CI = -29.26-83.01, p = 0.35).
“There was, however, no significant difference in faecal zonulin between PD and non-PD individuals”
Parkinson's disease increases brain age in Parkinson's disease patients (MAE 13.36 years (95% CI: 12.51-14.28)).
“213 showed higher and 2 showed lower predicted brain ages than their actual ages, with a mean MAE of 13.36 years (95% confidence interval: 12.51-14.28).”
In silicoin Parkinson's disease patientsbrainn = 215
Parkinson's disease is linked with worse postural control in humans (compared to healthy young adults).
“In stark contrast, older adults and individuals with Parkinson's disease exhibited control along suborthogonal directions that notably diverged from the AP and ML axes.”
Parkinson's disease impairs motor sequence recall in humans under sequence recall conditions (Z = 2.00, p = 0.045).
“Conversely, there was a significant group difference in the decrease of accuracy under recall conditions (Z = 2.00, p = 0.045), with the PD group showing a deviation from the distribution obtained under normal conditions (, lower panel).”
Human trialunder sequence recall conditions36 hours
Parkinson's disease impairs motor sequence recall in humans (motor sequence task).
“Participants with Parkinson's disease exhibited comparable performance to their healthy age-matched group with the exception of reduced performance in recalling motor sequences”
Parkinson's disease showed no clear effect on glucocorticoid receptor expression in mice (α-synuclein transgenic Parkinson's disease model versus age-matched controls).
“neither differences in HPA axis-related parameters nor in splenic GC receptor expression between PD and age-matched control mice”
Animalsα-synuclein transgenic Parkinson's disease model versus age-matched controlsspleen
Parkinson's disease was not clearly linked with time to perform the Timed Supine to Stand Test in humans (comparison with individuals without Parkinson's disease, controlling for age).
“Controlling for age via MANCOVA revealed no difference in range of motion, GRF, or time to perform the TSS.”
Humanscomparison with individuals without Parkinson's disease, controlling for age
Hip osteoarthritis was not clearly linked with Parkinson's disease in humans (Mendelian randomization using genetic variants as instrumental variables).
“In contrast, hip OA showed no significant association with PD.”
HumansMendelian randomization using genetic variants as instrumental variables
GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (secondary analysis vs sulfonylureas) (HR 0.56 (0.36-0.86)).
“In the secondary analysis, GLP-1 RA use was associated with lower risks of dementia compared with sulfonylureas (0.75 (0.61-0.93)) and PD (0.56 (0.36-0.86)).”
GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (prescribed to individuals with higher underlying risk).
“glucagon-like peptide-1 receptor agonists were prescribed to individuals with higher underlying risk yet were associated with reduced disease incidence.”
Humansprescribed to individuals with higher underlying risk
GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (compared with DPP-4i new users; iRBD and type 2 diabetes) (HR 0.02; 95% CI 0.001–0.20).
“GLP-1RA use was associated with a lower risk of PD (HR, 0.02; 95% CI, 0.001 - 0.20)”
Humanscompared with DPP-4i new users; iRBD and type 2 diabetesn = 148
GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (compared with sulfonylureas) (adjusted HR 0.81 [95% CI 0.68-0.96]).
“use of GLP-1 receptor agonists compared with sulfonylureas was associated with a lower risk of incident Parkinson's disease.”
GLP-1 receptor agonists are associated with Parkinson's disease in humans (Patients with type 2 diabetes initiating therapy; compared with new metformin users) (aHR 0.56, 95% CI 0.34–0.93).
“However, between years 5 and 10, GLP-1RA use was associated with a significantly lower PD risk (aHR, 0.56; 95% CI, 0.34-0.93).”
HumansPatients with type 2 diabetes initiating therapy; compared with new metformin usersbetween years 5 and 10
GLP-1 receptor agonists are linked with a lower risk of Parkinson's disease in humans (sIPTW-adjusted Cox model comparing new users with new DPP4i users) (23% lower risk; HR 0.77 (95% CI 0.63-0.95)).
“GLP-1RA users were associated with a 23% lower risk of PD than DPP4i users (HR, 0.77; 95% CI, 0.63-0.95)”
HumanssIPTW-adjusted Cox model comparing new users with new DPP4i usersn = 89,074
Smoking is linked with a lower risk of Parkinson's disease in humans (regular smoking) (adjusted HR, 0.70; 95% CI, 0.62-0.79).
“Regular smoking was significantly associated with elevated risks of lung cancer, ischemic heart disease, stroke, and all-cause mortality but with lower risk of PD (adjusted HR, 0.70; 95% CI, 0.62-0.79).”
Smoking is linked with a lower risk of Parkinson's disease in humans (former smoking in stroke survivors) (HR = 0.80).
“smoking (former: Hazard ratio [HR] = 0.80; current: HR = 0.66) and alcohol consumption (moderate: HR = 0.83; heavy: HR = 0.74) were associated with a lower risk of PD”
Smoking is linked with a lower risk of Parkinson's disease in humans (adjusted for age, race, sex, education level, APOE ε4 status, and other VRFs) (HR 0.36, 95% CI 0.21-0.61).
“Midlife current smoking (hazard ratio [HR] 0.36, 95% CI 0.21-0.61) was significantly associated with a lower PD rate”
Humansadjusted for age, race, sex, education level, APOE ε4 status, and other VRFs
Smoking is linked with a lower risk of Parkinson's disease in humans (1-4 years before diagnosis compared to non-smokers) (OR 2.02 [1.07-3.81] in non-smokers).
“The odds ratio (OR [95 % CI]) associated with PD in non-smokers was 2.02 [1.07-3.81] 1-4 years before diagnosis, compared to 1.36 [1.02-1.83] at >10-year intervals (linear trend, p = 0.012).”
Humans1-4 years before diagnosis compared to non-smokers1-4 years before diagnosisn = 502,304
Caffeine is linked with a lower risk of Parkinson's disease in humans (aOR 0.77, p < 0.0001).
“Weekly caffeine consumption (adjusted odds ratio [aOR] 0.77, p < 0.0001) and tobacco use for ≥ 5 years (aOR 0.83, p = 0.0009) were inversely associated with PD”
Caffeine is associated with Parkinson's disease in humans (especially in observational studies).
“The findings indicate a consistent inverse association between caffeine consumption and the risk of developing DP, often with a dose-dependent pattern, especially in observational studies.”
Journal of Kermanshah University of Medical Sciences·
Caffeine lowers the risk of Parkinson's disease (Regular consumption of caffeine or caffeinated coffee).
“regularly drinking caffeine or caffeinated coffee significantly reduces the risk of developing Alzheimer's disease, epilepsy, and Parkinson's disease.”
ReviewRegular consumption of caffeine or caffeinated coffee
Caffeine is associated with Parkinson's disease in humans.
“Studies have shown an interaction between caffeine with genetic variants of MAPT, SLC2A13, LRRK2, ApoE, NOS2A, GRIN2A, CYP1A2, and ADORA2A in modulating the risk of PD.”
Reviewin individuals with genetic variants of MAPT, SLC2A13, LRRK2, ApoE, NOS2A, GRIN2A, CYP1A2, and ADORA2An = 607,074
Movement disorders : official journal of the Movement Disorder Society·
Nitrogen dioxide is linked with a higher risk of Parkinson's disease in humans (10 years of continuous exposure at 90th vs 0.5th percentile) (OR 1.474 (95% CI: 1.379, 1.575)).
“for 10 years of continuous exposure to NO2 at the 90th versus the 0.5th percentile (i.e., 31.7 ppb vs. 3.7 ppb), the odds ratio for hospitalization with PD was 1.474 (95% CI: 1.379, 1.575)”
Humans10 years of continuous exposure at 90th vs 0.5th percentile10 years
Journal of neurology, neurosurgery, and psychiatry·
Nitrogen dioxide is linked with a higher risk of Parkinson's disease in humans (first hospitalization with a PD-related diagnosis) (IRR 1.07 (95% CI: 1.05, 1.08)).
“1.07 (95% CI: 1.05, 1.08), and 1.03 (95% CI: 1.02, 1.05) for an interquartile range increase in PM2.5 (3.72 μg/m3), NO2 (13.84 ppb)”
Humansfirst hospitalization with a PD-related diagnosis13.84 ppb IQR increaseannual
Fine particulate matter is linked with a higher risk of Parkinson's disease in humans (per interquartile range (4.3 μg/m3) increase) (HR 1.018, 95% CI 1.008-1.028).
“each IQR increase in PM2.5 (4.3 μg/m3) and O3 (7.3 ppb) was associated with a modestly increased PD incidence (PM2.5: HR = 1.018, 95% CI: 1.008-1.028”
Humansper interquartile range (4.3 μg/m3) increase
Movement disorders : official journal of the Movement Disorder Society·
Fine particulate matter is linked with a higher risk of Parkinson's disease in humans (10 years of continuous exposure at 90th vs 0.5th percentile) (OR 1.634 (95% CI: 1.489, 1.792)).
“the odds ratio for hospitalization with PD was 1.634 (95% CI: 1.489, 1.792)”
Humans10 years of continuous exposure at 90th vs 0.5th percentile10 years
Movement disorders : official journal of the Movement Disorder Society·
Fine particulate matter is associated with Parkinson's disease in humans (Single-pollutant model) (HR 2.65 (95% CI 2.59–2.72)).
“exposure to PM2.5 (HR 2.65 (95% CI 2.59 to 2.72)), PM10 (HR 3.13 (3.04 to 3.22)), NO2 (HR 1.74 (1.68 to 1.80)) and SO2 (HR 1.68 (1.65 to 1.71)) was associated with an increased risk of PD.”
Journal of neurology, neurosurgery, and psychiatry·
Fine particulate matter is linked with a higher risk of Parkinson's disease in humans (first hospitalization with a PD-related diagnosis) (IRR 1.08 (95% CI: 1.07, 1.10)).
“incidence rate ratios of 1.08 (95% CI: 1.07, 1.10), 1.07 (95% CI: 1.05, 1.08), and 1.03 (95% CI: 1.02, 1.05) for an interquartile range increase in PM2.5”
Humansfirst hospitalization with a PD-related diagnosis3.72 μg/m3 IQR increaseannual
Diabetes mellitus is linked with a higher risk of Parkinson's disease in humans.
“Analysis of the CHARLS data showed that aging, urban residence, and metabolic diseases such as diabetes, hypertension, and dyslipidemia were significantly associated with the risk of PD”
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·
Diabetes mellitus is associated with Parkinson's disease in humans (history of stroke) (HR 1.38, 95% CI 1.25–1.52 for diabetes duration ≥5 years; P for trend <.001).
“particularly in those with a duration of diabetes mellitus of ≥5 years (HR = 1.38, 95% CI, 1.25–1.52).”
Humanshistory of strokediabetes mellitus for ≥5 years
Diabetes mellitus is linked with a higher risk of Parkinson's disease in humans (prior to diagnosis).
“Our findings show that certain disorders elevate AD and PD risk before AD and PD diagnosis including: insulin and non-insulin dependent diabetes mellitus, noninfective gastro-enteritis and colitis, functional intestinal disorders, and bacterial intestinal infections”
Diabetes mellitus raises the risk of Parkinson's disease in individuals with diabetes mellitus.
“Chronic hyperglycemia and insulin resistance, which characterize diabetes mellitus (DM), have been reported to alter dopaminergic activity, increase the risk of PD”
Parkinson's disease is associated with mortality in humans (Hospitalized COVID-19 patients in Brazil; multivariable analysis) (Adjusted OR 1.277, 95% CI 1.198–1.360).
“Multivariable analysis confirmed Parkinson's disease as an independent mortality risk factor (OR = 1.277; 95% CI = 1.198-1.360).”
HumansHospitalized COVID-19 patients in Brazil; multivariable analysisMarch 2020 to March 2024n = 1,725,690
Parkinson's disease is associated with mortality in humans (Patients with cancer; adjusted for potential confounders) (Adjusted HR 1.37, 95% CI 1.25–1.51).
“Comorbid Parkinson's disease was independently associated with 5-year mortality”
HumansPatients with cancer; adjusted for potential confounders5 yearsn = 118,999
Parkinson's disease is linked with a higher risk of mortality in humans.
“Individuals with PD have a significantly higher risk of all-cause mortality compared to those without PD (HR = 1.747 [1.363-2.238], P < 0.001) among adults.”
Frailty is associated with Parkinson's disease in humans (five years prior to PD diagnosis) (OR = 1.70, 95% CI 1.62-1.78).
“Mildly frail (OR = 1.70, 95 % CI 1.62-1.78) and moderately-to-severely frail (OR = 1.29, 95 % CI 1.16-1.43) were associated with PD five years prior to diagnosis.”
Parkinson's disease predicts frailty in humans (cause-specific HR 1.66 (95% CI 1.07-2.56)).
“cause-specific hazard ratios were 1.66 (95% CIs 1.07-2.56), 1.78 (95% CIs 1.05-3.03), and 1.58 (95% CIs 0.91-2.74). Similar results were found for parkinsonism.”
Parkinson's disease is associated with frailty in humans (OR 2.49 (95% CI 1.87-3.31)).
“PD was associated with baseline and incident frailty after accounting for age, sex, and education: odds ratios and 95% confidence intervals (95% CI) for frailty were 2.49 (95% CIs 1.87-3.31)”
SGLT2 inhibitors are associated with Parkinson's disease in humans (ranked lowest in PD risk among older adults).
“Rank probability analyses suggested that sodium-glucose co-transporter-2 inhibitors (SGLT2i) tended to rank lowest in PD risk among older adults (≥75 years)”
SGLT2 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with DPP-4i new users; iRBD and type 2 diabetes) (HR 0.03; 95% CI 0.001–0.97).
“SGLT-2i use was associated with a lower risk of PD (HR, 0.03; 95% CI, 0.001 - 0.97), parkinsonism (HR, 0.02; 95% CI, 0.001 - 0.87)”
Humanscompared with DPP-4i new users; iRBD and type 2 diabetesn = 138
SGLT2 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with metformin users in T2DM patients) (28% lower; aHR 0.72 (95% CI 0.62-0.84)).
“SGLT2i users had a 28% lower adjusted hazard ratio (aHR) for PD (0.72; 95% CI, 0.62-0.84)”
Humanscompared with metformin users in T2DM patientsn = 913,428
SGLT2 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with other oral antidiabetic drugs; 6-month drug use lag period) (aHR 0.80 (95% CI 0.69-0.91)).
“and PD (aHR 0.80, 95% CI 0.69-0.91)”
Humanscompared with other oral antidiabetic drugs; 6-month drug use lag periodn = 358,862
SGLT2 inhibitors are linked with a lower risk of Parkinson's disease in humans (compared with DPP4 inhibitors, after 1:1 propensity score matching) (HR 0.70 [95% CI 0.55-0.89]; 2.5 vs 3.5 events per 1000 person-years).
“The SGLT2 inhibitor group was associated with a significantly lower risk of incident PD than the DPP4 inhibitor group”
Humanscompared with DPP4 inhibitors, after 1:1 propensity score matching
Retinal vessel density is associated with Parkinson's disease in humans (disease duration in patients with Parkinson's disease undergoing yoga) (r = -0.67).
“Changes in RVD were significantly correlated with disease duration (r = -0.67; P = 0.007)”
Human trialdisease duration in patients with Parkinson's disease undergoing yogaretina24 weeksn = 17
Compared with unexposed veterans, those reporting exposure had a higher relative risk of Parkinson disease diagnosis, with a hazard ratio of 1.44.Compared with unexposed veterans, those reporting exposure had a higher relative risk of Parkinson disease diagnosis, with a hazard ratio of 1.44.
The model scored 0.93 on a measure of how well it distinguished 133 people with Parkinson’s from 26 healthy controls.The model scored 0.93 on a measure of how well it distinguished 133 people with Parkinson’s from 26 healthy controls.